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Benefits of Nitric Oxide Cues to Matrix Synthesis by Healthy and Aneurysmal
Human Smooth Muscle Cells within 3D Cocultures

PHILLIP SIMMERS

ABSTRACT
Vascular diseases such as atherosclerosis and aneurysms are characterized by the
over-proliferation and migration of aortic smooth muscle cells (SMCs), and degradation
of extracellular matrix (ECM) within the vessel wall, leading to compromise in cell-cell
and cell-matrix signaling pathways. Recent tissue engineering approaches to regulate
SMC over-proliferation and enhance healthy ECM synthesis showed promise, but
resulted in low crosslinking efficiency and matrix deposition yields. In this study, the
benefits of exogenous nitric oxide cues, delivered from S-Nitrosoglutathione (GSNO), to
cell proliferation and matrix deposition by adult human aortic SMCs (HA-SMCs) within
3D biomimetic cultures have been explored. The first experiment utilized a microfluidic
platform with two adjacent, permeable 3D culture chambers, to enable paracrine
signaling between vascular cell cocultures. Healthy HA-SMCs were cultured in these
devices within 3D collagen hydrogels, either alone or in the presence of human aortic
endothelial cell (HA-ECs) cocultures, and exogenously supplemented with varying
GSNO dosages (0-100 nM) for 21 days. Results showed that EC cocultures stimulated
SMC proliferation within GSNO-free cultures. However, with increasing GSNO
concentration, HA-SMC proliferation decreased in the presence or absence of EC
cocultures, while HA-EC proliferation increased. GSNO (100 nM) significantly enhanced
the total protein amount synthesized by HA-SMCs, in the presence or absence of EC
v

cocultures, while lower dosages (1-10 nM) offered marginal benefits. On a per cell basis,
multi-fold increases in the synthesis and deposition of elastin, glycosaminoglycans,
hyaluronic acid and lysyl oxidase crosslinking enzyme (LOX) were noted at higher
GSNO dosages, and coculturing with ECs significantly furthered these trends. The matrix
yields of these proteins reached almost 40 - 51 % within selective cocultures receiving
GSNO. Similar increases in TIMP-1 and MMP-9 levels were noted within cocultures
with increasing GSNO dosages, although MMP-2 levels remained attenuated. These
quantitative assay data were strongly supported by immunofluorescence images under
respective conditions. Based on the optimized dosage (100 nM) deduced from first
experiment, we tested the utility of NO cues within diseased HA-SMC (derived from
aneurysmal human aortic segment) cultures, under both 2D and 3D culture conditions.
Results showed that cell proliferation was higher on 2D substrates compared to that
within 3D cultures. In accordance to the trends noted within healthy SMC cultures, there
was a decrease in cell proliferation in both 2D and 3D, with increasing GSNO dose.
Similarly, the presence of GSNO stimulated elastin, glycosaminoglycans, hyaluronic
acid, lysyl oxidase crosslinking enzyme (LOX), MMP-2, 9 and TIMP-1 synthesis and
release by aneurysmal SMCs, although the matrix deposition levels were lower compared
to their healthy counterparts. Both experiments results attest to the tremendous benefits
of delivering nitric oxide cues to suppress SMC proliferation and promote robust ECM
synthesis and deposition by adult human SMCs, with significant applications in tissue
engineering, biomaterial scaffold development, and drug delivery.
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CHAPTER I

BACKGROUND

1.1. Vascular tissue organization
Excluding the capillaries and the venules of the peripheral circulation system, all
blood vessel walls are composed of three distinct layers: tunica intima, tunica media, and
the tunica adventitia (Fig. 1.1). The tunica intima is the inner most layer, which is
composed of endothelium and a connective tissue basement membrane. Following the
basement membrane is a layer of smooth muscle and connective tissue called the lamina
propria. Encapsulating the lamina propria is the internal elastic membrane, which consist
primarily of elastic fibers. Following the tunica intima is the tunica media which is a
layer of smooth muscle cells with a circular arrangement. This is the layer that allows for
the movement of blood through the vessel through contraction and relaxation. Just like
the outer layer of the tunica intima the tunica media has an elastic membrane that
separates it from the tunica adventitia. The last layer, or the tunica adventitia, is
1

composed of dense connective tissue near the tunica media and gradually transitions to
loose connective tissue in order to merge the blood vessels with the surrounding tissue1.

Figure 1.1 The layers of the blood vessel2.

1.2. Vascular extracellular matrix
Vascular tissue as described previously is broken up into three different layers. The
composition of the extracellular matrix adds to the overall properties of the individual
layers and is dependent on the cell phenotype located in the layer. The tunica intima
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connective tissue is very thin and primarily made of endothelial cells with little matrix
while the smooth muscle cells in the tunica media deposit and upkeep the internal and
external elastic lamina which are responsible for the pulsatile stretching forces
experienced in the arterial walls. Lastly, the fibroblast located in the tunica adventitia
deposit much of the collagen found in the vascular tissue1. The description of the most
important extracellular matrix proteins of the vascular tissue can be found below.

1.2.1. Collagen
The most abundant protein found in ECM is collagen which plays an integral role in
providing both support and tensile strength to the vascular tissue. Collagen exists in
many different types in the human body, but the most common one found in vascular
tissue is type I, which comprises 80% of the total collagen found. Type III makes up
12% of collagen found with the last 8% being composed of trace concentrations of types
IV, V, and VI collagen. The structure of all collagen is that of a triple helix that are
constructed with α-chains. It is the altercations in the α-chains that result in the formation
of different collagen types. The glue that holds the triple helix structure of collagen
together is the chemical bonds between the hydroxylated amino acids of proline and
lysine. The fibrous nature of collagen I, III, and V aggregates together to create larger
fibers. These fibers are the main structural support of the tissue and connect main
vascular tissue components3–8. Cells are able to migrate along the collagen fiber through
the use of fibronectin9.
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1.2.2. Glycosaminoglycans
Glycosaminoglycans (GAGs) are anionic polysaccharides with hydrophilic chains
that have many disaccharide units. There are two main types of GAGs, those with and
those without sulfated groups attached to the sugar molecules. Further categorization of
GAGs focuses not only on sulfate groups, but the types of sugars and their bonding
characteristics. The four main groups of GAGs are; hyaluronan, chondroitin sulfate,
heparin sulfate, and keratin sulfate. The only GAG that is non-sulfated in its disaccharide
unit is the hyaluronic acid (HA) molecules4,6,10.
GAGs are known mainly for their hydrophilic properties that allow them to expand
forming hydrogels. This occurs by the large negative charges on their surface, which
attract many cations that are osmotically active, to successfully attract water into the
GAG matrix. Mechanically, GAGs are resistant to compression and thus help vascular
tissue to keep its physical integrity from exterior forces. Also sulfated GAGs are able to
covalently bond to other proteins, which form structures commonly known are
proteoglycans9.
Proteoglycans perform a wide range of functions for the surrounding cells. One
proteoglycan unit consists of a protein core attached to covalently bonded GAG chains.
They provide the necessary hydrated space around cells, regulate the passage of certain
molecules, bind to growth factors and other signaling proteins for signal transduction, and
guide cell migration through the extracellular matrix9.
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1.2.3. Elastin
One of the most essential ECM protein of the vascular system, elastin provides the
necessary elastic properties allowing for blood to be properly pumped through the
circulatory system by bearing the mechanical pressure applied to the tissue during the
cardiac cycle9. Elastin is formed when soluble monomers, tropoelastin and fibrillin, are
cross-linked by the enzyme lysyl oxidase (LOX) forming an insoluble protein. Fibrillin
is a glycoprotein that is essential in the formation of elastic fibers. Each type of fibrillin
performs a different function in the formation of fibers with fibrillin-I performing the
most important function in elastin formation. Fibrillin-1 serves as a structure glue
component of calcium by binding microfibrils (i.e. tropoelastin). The microfibrils then
provide the structural integrity of tissues as well regulation of cytokines through the
sequestration of molecules. The majority of elastin is synthesized during the neonatal
developing stages, or the period from birth to one month old, and there is a significant
decrease in the synthesis of mature matrix elastin in adults. Elastin is not only important
due to the mechanical properties it contributes to the overall tissue but it has been also
noted to regulate SMC proliferation and morphology11–14 .

1.2.4. Lysyl oxidases
Lysyl oxidases (LOX) are an extracellular copper enzyme that can catalyze aldehydes
from lysine residues in tropocollagen and tropoelastin. The aldehydes are highly reactive
and thus spontaneously react with lysyl oxidase derived aldehyde residues resulting in the
cross-linking of collagen and elastin, which successfully stabilizes the collagen fibrils as
well as develops mature matrix elastin15 .
5

1.2.5. Matrix metalloproteinases and their inhibitors
Matrix metalloproteinases (MMPs) are naturally occurring extracellular proteolytic
enzymes that degrade ECM proteins. During periods of inflammation these enzymes are
upregulated in order to destroy the ECM to make room for inflammatory cells. MMPs
are able to break down much of the ECM proteins by attacking the cross-linkers that hold
many of the proteins together. To ensure that MMPs are not left unchecked, the synthesis
of tissue inhibitors of metalloproteinases (TIMPs) is necessary for protection of nondamaged tissue. TIMPs are protease–specific and bind to activated proteases during the
inflammatory phase restricting the activity of MMPs6,8 . Thus, a careful balance of both
TIMP and MMP expression is needed to properly reorganize vascular ECM.

1.3. Vascular aneurysm
When vascular elastin is congenitally malformed, or damaged by local injury, or
degraded by acquired diseases, it severely compromises vessel integrity, disrupts cellular
signaling pathways, initiates inflammation, and weakens vessel wall16. This can lead to
an aneurysm or the ballooning/dilation of an artery. Aneurysms can come in two general
shapes as seen in Fig.1.2. The first is the formation of a pouch or sac on one side of the
blood vessel wall and is commonly known as a saccular aneurysm. The second is called
the fusiform aneurysm and is commonly defined as the dilation of the artery in all
directions17. Hypertension of this area can lead to a burst in the vessel and thus
hemorrhage of blood into the surrounding tissue1. Under such non-healthy conditions,
elastin gene expression is down-regulated, and the mature elastin is degraded by MMPs
and macrophage-derived elastases (cytokines, interleukins) into soluble peptides, which
6

furthermore interrupts elastin-SMC signaling pathways18–23. Such elastin disruption
encourages SMC hyper-proliferation and medial thickening, leading to reduced arterial
compliance, hypertension and aneurysm of the vessel24–29. The ability for vascular tissues
to self-repair is hampered by their inherently complex matrix structure and compromised
cell-signaling pathways.
The development of aneurysms might be one of the most prevalent cardiovascular
conditions, possibly affecting up to 90% of people30. Due to the possibility of living with
an aneurysm without it rupturing, as well as poor diagnosing methods, many conditions
go untreated creating for an even larger risk. Besides, understanding the mechanisms
leading to hypertension remain broadly unidentified31. As explained previously, the
mechanical properties of cardiac tissue are obtained from the ECM, mainly the elastin
and collagen fibers32. Since elastin functions mainly at lower pressures than collagen, the
hypertension of vessel walls can be accounted for the degeneration of elastin, leading to
many cardiac diseases31.
Abdominal aortic aneurysms (AAA) is the extension of an abdominal aortic section,
usually developing over several years, and is currently the 10th leading cause of death in
the United States, killing roughly 15,000 people annually33. As stated previously, many
of these cases are left undiagnosed and untreated, which results in a high mortality rate
~75-90%34. Many of the cases discovered are done so by accident during routine
physical or radiographic exams on an unrelated symptom34 and only six countries in the
world offer a clinical screening procedure standard35. Other than the risk of rupture, the
disruption of flow in the aneurysmal blood vessel can cause a multitude of symptoms
depending on the type and location of the aneurysm, including; headaches, blurred or
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double vision, weakness or numbness. The disruption of flow has been shown to change
its direction to an anterior pathway moving along the proximal wall of the aneurysm
creating a vortex36.
A

B

Figure 1.2 Different types of aneurysm formations (A) saccular and (B) fusiform17.

1.4. Approaches for aneurysm treatment
As mentioned previously, early diagnosis of an aneurysm rarely occurs due to the
lack of symptoms paired with the fact that many symptoms are not exclusive to
aneurysms. The lack of early detection can lead to rupture of the aneurysm and
depending on the severity of the hemorrhage death may result. The discovery a
throbbing mass or the abnormal sound of rushing blood flow during a routine physical
examinations can lead to further procedures including ultrasound, computed tomography
8

scan (CT), magnetic resonance imaging (MRI), or an angiography which will properly
show the size and location of the aneurysm. Following the diagnosis of an aneurysm
doctors will determine if surgical, pharmacological, or a mixture of both is best for the
treatment. Treatment can also be in the form of altering patient behavioral factors which
include the elimination of stressful situations, physical labor, smoking and unhealthy
foods.

1.4.1. Surgical and Pharmaceutical approaches for aneurysm treatment
As described in the History of Aneurysms by W. E. Stehbens, treatment of aneurysms
dates all the way back to the fourteenth century B.C. to the time of the Egyptians37.
Treatment of aneurysms was first noted in 1817, when William and John Hunter
performed the first ligation of an aneurysm38. The procedures evolved when the
revolutionary surgical technique of endoaneurysmorrhaphy was developed in 1888 by
Rudolf Matas39. In endoaneurysmorrhaphy the aneurysm is opened and then collapsed
on itself through a series of folding to return the lumen of the blood vessel to is normal
size and then sutured back together.
In the 1940’s, advances in the treatment of congenital heart surgery lead to many of
the modern surgical treatments of aneurysms. Here a ruptured aneurysm was first
patched successfully utilizing a pectoralis muscle patch by Dr. Denton Cooley and Grant
Ward40. This experience was vital for Dr. Cooley (along with Dr. Michael DeBakey) as
he would later develop the tangential excision and lateral aortorrhaphy, which is the
clamping of a saccular aneurysm at its neck and then removing the ballooned portion of
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the artery41. Following their innovative treatment method Dr. Cooley and DeBakey were
able to refine and apply the use of homografts in many new areas41–47.
The next chapter of surgical treatments for aneurysms was started by Dr. Cooley in
1963 when he founded the Texas Heart Institute40. The Texas Heart Institute has
decreased surgical mortality from 50% to 10% by modifying the Bentall and Cabrol
procedure as well as perfecting bypass surgeries48,49. Lastly in 1981, Dr. Cooley
innovative thinking led to the preparation of woven Dacron grafts, which he helped
develop in 197850, by soaking them in the patient’s own plasma and then autoclaved it
which sealed the interstices of the graft with the coagulated protein. By doing this Dr.
Cooley was able to reduce the post-surgery bleeding as well as start a standard for
manufacturing of grafts today49,51.
Besides open surgery techniques as described above, some aneurysms are able to be
treated through a minimally invasive endovascular method. Two of the most common
are stent graft repair and coil filling systems52,53. Both of these methods access the
cardiovascular systems from a peripheral artery, and the most widely used in clinical
settings currently. In the stent method the stent is put into place by a catheter and when
in place, expands which allows blood to safely flow through and prevent any further
damage to the aneurysm. As for the coil systems, they are utilized predominately in
saccular aneurysms located in the brain due to the difficulty in performing open surgery.
Similar to the stent, coil systems are loaded into a catheter and directed to the aneurysm
site where they are deployed successfully filling up the ballooned area and sealing it from
the artery.
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In conjunction to surgical treatment route, pharmaceutical options are available.
Medications (statins) can be used to combat a patient’s high level of cholesterol which
leads to an increase risk in atherosclerosis (a leading cause of aneurysms). Statins can
block the enzymes necessary for the production of cholesterol, thus reducing the levels of
cholesterol in the blood. Other drugs such as fibric acid derivatives, bile acid
sequestrates, or nicotinic acid can also be used to control the cholesterol levels in the
blood54. For treatment in patients already diagnosed with an aneurysm, beta-blockers are
commonly prescribed as they can lower heart rate, and consequently the volume of blood
pumped which ultimately lowers the blood pressure55.

1.5. Tissue engineering approaches for aneurysm treatment
Tissue engineering is one avenue which within the last decade has made major strides
in alleviating and identifying vascular aneurysms. Specifically improved
biocompatibility of graft materials as well as cell delivery techniques for repair and
regeneration of many cardiac diseases are one of several advances within the field that
may one day lead to total vascular replacement; however these types of vascular conduits
are limited by their dimensions, composition, and host response. The first tissue
engineered vessel was created in 1986 by Weinberg and Bell56 when they cultured bovine
endothelial cells with smooth muscle cells and fibroblast in artificial blood vessels that
had multiple layers of collagen and a Dacron mesh57. Culturing of the smooth muscle
cells and fibroblast in the presence of vitamin C created an extracellular matrix that
mimicked nearly to the in vivo characteristics58. Recently, several groups have attempted
to utilize are ePTFE, Dacron, and polyurethanes for total vascular replacement but have
11

been unable to fully overcome host immune reaction59. Minimization of this
immunogenic response can be achieved through surface treatment of the material using
proteins, cells, and other polymers60–62 which control the formation of thrombosis as well
as hyperplasia within implanted grafts. Still the porous nature of these constructs allows
for the diffusion of certain element into surrounding tissue. Lastly, Cambell et al. showed
that when silastic tubing was inserted into the peritoneal cavity of rats and rabbits that it
would cover the tubes with layers of myofibroblasts, a collagen matrix as well as a
monolayer of mesothelial cells due to the inflammatory reaction. Once removed and
turned inside out, the structure of the vessel mirrored that of normal tissue63.
Another approach beside synthetic constructs is the use of acellular extracellular
scaffolds formed from dehydrated mammalian tissue which can then be wrapped around
a cylindrical mandril which gives it a tubular shape. Smooth muscle cells obtained from
stem sources (embryonic, umbilical, and mesenchymal) can then be inserted into these
lumens to form the vascular media. Finally after a week in a bioreactor or other growth
stimulating conditions, these types of scaffolds can be implanted into host tissue and
tested for viability57. Similarly, other groups have utilized a pulsatile flow in their
scaffold design to help mature the tissues of their artificially constructed graphs to aid in
their mechanical properties, specifically increased smooth muscle cell density, collagen
density. One group reported on the addition of aortic smooth muscle cells placed in a
silicone tube for 8 weeks with media pumped through at 165 beats per minute and 5%
radial expansion64. In general, total vascular replacement is a promising option for those
diagnosed with aneurysms; however currently due to the infancy of the field these
approaches are not yet suitable for human trials.
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1.6. Role of nitric oxide
Nitric oxide (NO) is an important signaling molecule that has a wide array of
biological applications. NO is a small and relatively stable free-radical gas that readily
diffuses into cells and interacts with molecular targets65. For the purpose of this thesis
the studies of nitric oxide in cardiac tissue have been reviewed and their overall findings
and scope of the experiments performed are mentioned in this section.
As discovered by Moncada et al., NO is synthesized from L-arginine substrate66 and
inhibited by NG-monomethyl-L-arginine67. This group also discovered that the NO
pathway existed in multiple tissues showing that NO is used in a wide range of cellular
functions and communication68–70. They also claim that NO is an important regulator in
blood pressure, platelet activation, as well as neurotransmission71,72.
The work on the effects of NO on matrix synthesis ability by human vascular cells is
lacking, but there has been work reported on vascular cells in other organisms. For
example the administration of NO substrate was shown to suppress the induced
pulmonary vascular disease in rats as well as eNOS+ mice that exhibited increased
pulmonary hypertension and vascular disease caused by chronic hypoxia72,73. This study
shows that in rats that were treated with NO inhalation both reduced pulmonary vascular
resistance as well as artery pressure by successfully dilating pulmonary vascular tissue.
This shows that in the absence of NO leads to vasoconstriction and hypertension leading
to many vascular diseases73 as well as a decreased inflammatory response72. A similar
study utilizing chick aortic SMCs show that the delivery of NO inhibits the proliferation
of the cells and stimulates the expression of tropoelastin and LOX mRNA74. These
studies give enough support to the possibility of utilizing exogenously delivered NO to
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activate SMCs enzyme release, upregulate elastin synthesis and crosslinking through
LOX upregulation, and return to normal homeostasis in diseased tissues.
The experiments described in this thesis utilize S-Nitrosoglutathione (GSNO) as a
NO donor (Fig. 1.3). It has been previously found that the formation and decay of low
molecular weight S- nitrosothiols (such as GSNO) may represent a mechanism for the
storage or transport of NO75,76. Besides GSNO, other S-nitrosothiols include Snitrosocysteine (CySNO) and S-nitroso-N-acetyl-DL-penicillamine (SNAP). GSNO is a
preferred choice because it can be naturally occurring within the cell cytoplasm, has a
low molecular weight of 336.32 (which allows for rapid diffusion across a scaffold), and
possesses many different documented benefits to smooth muscle tissue such as protection
against ischemic myocardium by increasing perfusion77. The decomposition of the Snitrosothiols, mainly the hemolytic cleavage of the S-N bond78, leads to NO release and
thiyl radicals (GSH)79. It is also important to mention that the formation of Snitrosothiols from endogenous NO intermediates readily reacts with glutathione to form
naturally occurring GSNO80,81. Singh et al. showed that NO cleavage from GSNO
readily occurs in the presence of light as well as transition metal ions. This group also
claims that there is a transfer of NO+ from an S-nitrosothiol to a thiol79, this occurs
through the presence of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH
oxidizing substrate) and thioredoxin reductases in vivo82. It could be postulated that the
combination of metal ion chelators, specifically Cu2+ found in human smooth muscle cell
cultures, along with additional cleavage occurring within the cell cytoplasm through the
NADPH oxidizing substrate provides the necessary mechanism behind NO cleavage from
GSNO molecules. For instance Singh et al. showed that GSNO released roughly 3/4ths of
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its NO within 30 minutes and over 600 µM of NO from 1 mM GSNO in the presence of
Cu2+79.

Figure 1.3 Chemical structure of S-Nitrosoglutathione83
Within physiological systems NO has many different functions in redox signaling84–
87

. Specifically, NO targets thiols that are specifically S-nitrosylated. The nitrosylation

of a Cys-residue in p21ras activates the G protein, which plays a critical role in converting
extracellular signals into intracellular biochemical events. Finally, the oxidation of NO
in vivo has been proven to be very slow and insignificant process making it a relatively
stable structure in the absence of glutathione which creates endogenous GSNO88.
1.7. Organization of thesis
Data obtained in this thesis was organized into two separate experiments with the
goal to describe the effects of delivering nitric oxide cues on HA-SMC proliferation,
synthesis and deposition of vascular ECM (elastin, glycosaminoglycans, hyaluronic acid),
release of inflammatory markers (MMPs-2, 9) and their inhibitors (TIMP-1), as well as
matrix crosslinking enzymes (LOX). The first of these experiments utilized cocultures of
HA-SMC and HA-EC. This was accomplished in both in a 3D microfluidic platform as
well as 3D culture wells. The innovative microfluidic design allowed for paracrine
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signaling as well as more physiologically relevant imaging while the culture wells
allowed for quantitative analysis of the effects of both NO cues as well as HA-ECs on
HA-SMCs. The second experiment was designed to utilize the key data obtained in the
first and applied to diseased HA-SMCs with the exception of coculturing platform.
Unlike the first experiment, culture wells were utilized in both 2D and 3D in order to
properly translate data obtained in this thesis to future clinical relevance. This thesis was
designed to obtain a thorough understanding of the exogenously delivered NO on both
healthy as well as diseased HA-SMCs to be relevant for drug and toxicology screening,
tissue engineering and regenerative medicine therapies, as well as vascular disease
remodeling.
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CHAPTER II

MATERIALS AND METHODS

2.1. Microfluidic platform fabrication
Coculturing vascular cells within 3D scaffolds, in close proximity to enable paracrine
signaling, is difficult to accomplish using conventional cell culture techniques. This
might partially explain the paucity of literature on this subject. Recent developments in
microfluidic platforms might help overcome these limitations. The microfluidic device
utilized in this study was created using photolithography and soft-lithography techniques
as we detailed earlier89. Briefly, the device was designed in SolidWorks (SolidWorks
Corp., Waltham, MA) and the mold developed at Stanford Microfluidics Foundry. Using
this mold, microfluidic devices (Fig. 2.1) were created by replica molding with
polydimethylsiloxane (PDMS: Dow Corning). PDMS was mixed with curing agent (10:1
ratio), degassed and cured, removed from the mold and cut into separate devices. The
devices were then sterilized in boiling water (45 min), and dried (80 °C, 2 h). The glass
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cover slips were cleaned with ethanol and air plasma treated along with PDMS devices
for 1 min before bonding, and devices stored till usage in a sterile environment.

Figure 2.1 (A) Design of the microfluidic device for enabling biomimetic cocultures. (B)
Cells could be cultured either alone or in the presence of other cell types within
designated chambers of the device. These cell chambers have individual gel-filling ports,
separated by microfluidic pillar posts, and could be supplemented with media through
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separate channels. (C-E) HA-SMCs were cultured within collagen scaffolds, in the
presence or absence of EC coculture and exogenous GSNO (0-100 nM dosage).

2.2. Cell culture
Healthy adult human aortic smooth muscle cells (HA-SMCs) and human aortic
endothelial cells (HA-ECs) were obtained from Life Technologies Corp. (Carlsbad, CA)
and passaged using appropriate media (Medium 231 and Medium 200, respectively; Life
Technologies) provided. Diseased adult human aortic smooth muscle cells (HA-SMCs)
were isolated from abdominal aortic aneurysm segment of a 54-year old male, and
provided at passage 2 by collaborators at INSERM U698, Paris, France. These cells were
passaged in our lab using appropriated media (Medium 231; Life Technologies). For
experiments in this study, we used cells from passages 3-5 for healthy cells and 2-3 for
diseased cells. Collagen gel (2 mg/ml; pH ~ 7.4) was prepared by mixing collagen stock
solution (type-1, rat-tail derived, BD Biosciences, Bedford, MA) with a mixture of 10
PBS, 1 M NaOH and DI water.

2.2.1 Healthy cell cultures
Two sets of cultures were performed in parallel: (i) HA-SMCs cultured alone, and (ii)
HA-SMCs co-cultured with HA-ECs both in a well as well as a microfluidic platform.
Results from the former set serves to (a) establish baseline data for adult human aortic
SMC 3D cultures, (b) act as a control for the adult vascular 3D coculture data, and (c)
rapidly scale up this process for further in vitro or in vivo studies. SMCs or ECs were
mixed in 2 mg/ml collagen at a density of 10,000 cells per chamber. The device has two
separate but adjacent 3D chambers (Fig. 2.1), each with individual gel-loading ports and
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media channels. As shown in Fig. 2.1, in devices where SMCs were cultured alone,
collagen gel containing SMCs were injected in the right chamber of the device, and
collagen gel containing no cells in the left chamber. Similarly, in cases where cocultures
were performed (Fig. 2.1), collagen gel containing ECs were injected in the left chamber,
and gel containing SMCs in the right chamber. In this fashion, each cell type received its
own media and GSNO dosage, but still in constant diffusive contact with neighboring cell
type. Gels were injected into the respective gel-loading chambers with a cold-pipette tip
containing ~7 µl of collagen solution. The devices were placed in a humidified incubator
(37 °C, 30 min) to polymerize the collagen. Upon polymerization, cells were cultured for
21 days in either SMC or EC media, containing S-Nitrosoglutathione (GSNO; Sigma,
Saint-Louis, MO), an NO donor.
As detailed in Fig. 2.1 (cases 1 and 2), four different concentrations of GSNO (0, 1,
10, 100 nM) were tested for their ability to induce changes in SMC proliferation and
matrix synthesis. GSNO concentration at 0 nM acts as a control for higher GSNO
concentrations in each case. We choose not to coculture HA-SMCs with HA-SMCs (in
separate chambers), due to minimum benefits from autocrine signaling. These devices
could be scaled up in dimensions, for culturing larger gel volumes or higher cell
densities. As for the well culture platform 300 µl of collagen gel containing 10,000 cells
was seeded into a 48-well plate. Plates were placed in the humidified incubator (37 °C,
30 min) to polymerize the collagen and then cultured for 21 days in a similar method to
the microfluidic device. The main difference was that in the case of coculture the HA-EC
spent media was transferred to the HA-SMC cultures. Media was changed once a day
and the spent medium was pooled over the 21 day culture and stored at -20 °C for further
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biochemical analyses. Similarly, cell matrix layers at the end of 21 days were trypsinized
(one chamber at a time) and pooled from respective chambers and processed for
biochemical assays as detailed below.

2.2.1 Diseased cell culture
Two sets of cultures were performed in parallel: (i) Aneurysmal HA-SMCs cultured
on 2D substrates, and (ii) HA-SMCs cultured within 3D collagen hydrogels. To seed the
wells in 3D cultures, SMCs were mixed in 2 mg/ml collagen at a density of 10,000 cells
per well, while in 2D seeding the 24-well plates were first coated with a layer of 50
µg/ml collagen and then 10,000 cell were placed in each well. The cultures were placed
in a humidified incubator (37 °C, 30 min) to polymerize the collagen. Upon
polymerization, cells were cultured for 21 days in SMC media, containing SNitrosoglutathione (GSNO; Sigma, Saint-Louis, MO), an NO donor. Two different
concentrations of GSNO (0 and 100 nM) were tested for their ability to induce changes in
SMC proliferation and matrix synthesis, based on outcomes identified in healthy cell
cultures. A total of 12 wells were seeded for both 2D and 3D cultures per concentration
of GSNO. GSNO concentration at 0 nM acts as a control for higher GSNO
concentrations in each case. Media was changed once a day and the spent medium was
pooled into a single volume per case over the 21 day culture and stored at -20 °C for
further biochemical analyses. Similarly, cell matrix layers at the end of 21 days were
trypsinized (one chamber at a time) and pooled from respective chambers and processed
for biochemical assays as detailed below.
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2.3. Biochemical analyses
The characterization of the ECM synthesized by both the healthy and diseased HASMCs was performed by the assays as described in the sections below. For each of these
assays there were conducted on both the cell matrix as well as the pooled media (1 case
per assay with n=3 per case unless otherwise noted) following the 21 day culturing
period. For healthy cell cultures, cells were seeded within one well per assay due to
extremely low proliferation rate of adult HA-SMCs, low survival after passaging, and the
prohibitive costs in obtaining large cell densities required for seeding in larger number of
wells . To prepare each sample for their respective assay the cell matrices were detached
by incubating them with Trypsin 1 for 8-10 min. Once the cells were detached from
each well the suspensions were centrifuged at 2800-3000 rpm for 10-12 min. Following
the centrifugation, the supernatant was discarded leaving the pellet in the microcentrifuge
tube. The pellet were resuspended in 300 µL of 1x PBS. Similarly the pooled media that
was collected from each well and stored at -20 °C, was thawed and distributed in 1 mL
increments to labeled microcentrifuge tubes and centrifuged at 12000 rpm for 15 min.
Once the centrifuging was complete the supernatant was discarded and the pellet was
resuspended in 300 µl of 1x PBS. All samples were then stored in -20 °C until further
use. Before the start of any assay the samples were thawed at room temperature.

2.3.1. DNA assay for cell proliferation
The cell density within different cases was quantified at the end of both 1 and 21 days
to assess the proliferation of healthy or diseased HA-SMCs and HA-ECs over the culture
period. Briefly, media was removed from the media channels, and 0.25% v/v trypsin22

EDTA (Invitrogen) was added to the channels, cell layers were detached and extracted
separately from each chamber, pelleted by centrifugation, resuspended in NaCl/Pi buffer,
and assayed using a fluorometric assay, as we detailed earlier89. The cell density was
calculated on the basis of an estimated 6 pg DNA/cell90.

2.3.2. BCA assay for total protein synthesis
The total amount of protein synthesized by HA-SMCs under various culture
conditions was determined using bicinchoninic acid protein assay kit (BCA Kit, SigmaAldrich), as per the vendor’s protocols. Once thawed 25 µl of each sample were pipetted
into a 96-well plate (Greiner Bio One, Monroe, NC) along with the standards that were
prepared according to the venders protocol of 25 µg/ml, 125 µg/ml, 250 µg/ml, 500
µg/ml, 750 µg/ml, 1000 µg/ml, 1500 µg/ml, and 2000 µg/ml. To each of the wells
containing either a sample or a standard 200 µl of BCA working solution was added and
mixed on a mechanical shaker for 30 seconds. This assay is based on the principle that a
Cu2+-protein complex forms under alkaline conditions, followed by reduction of the Cu2+
to Cu1+ based on the amount of protein present in the sample and has a working range of
20-2000 µg/mL (all data obtained was within this range). The total protein in the pooled
spent media as well as in the cell matrix at the end of 21 days was quantified (n = 6
devices/condition).

2.3.3. Fastin assay for elastin protein
The amounts of matrix elastin and tropoelastin (in pooled spent medium) were
quantified using a Fastin assay (Accurate Scientific Corp, Westbury, NY, USA). Since
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the Fastin assay quantifies only soluble α-elastin, the matrix elastin was first reduced to a
soluble form and has a working range of 5-70 µg (all data was found within this range
and n=4 for healthy monocultures and cocultures). This was accomplished by digesting
the samples with 1 M oxalic acid at 100 °C for one hour. The samples were then
transferred to a 2 ml microcentrifuge tube and with an equal amount of elastin
precipitating reagent. Along with this step the elastin precipitating reagent was also
added to the blanks and standards (12.5 µl, 25 µl, and 50 µl). It is important to note that
both samples and standards were run in duplicate in accordance to the Fastin elastin assay
protocol. Once the elastin precipitating reagent was added to all samples and standards
each tube was vortexed and left at room temperature for 15 minutes. Following the 15
minutes the tubes were centrifuged at 10,000 g for 10 minutes and following the
supernatant was removed. The pellet containing the elastin precipitate was suspended in
1 ml dye reagent and homogeneously mixed on a mechanical mixer at room temperature
for 90 minutes. Following incubation, each tube was centrifuged as described above and
250 µl Dye dissociation reagent was added to each tube once the supernatant was
removed. The pellet was then dispersed by vortexing twice with a 10 minute interval.
The suspension was then transferred to a 96-well microplate and the absorbance was
measured at 513 nm with a microplate spectrophotometer. The measured amounts of
matrix elastin and tropoelastin were normalized to their respective cell counts to provide
a reliable basis of comparison between samples.
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2.3.4. sGAG assay for glycosaminoglycan synthesis
The amounts of sulfated glycosaminoglycans deposited within the cellular matrix as
well as in the pooled spent medium were quantified using a quantitative dye-biding
sGAG Assay (Kamiya Biomedical Company, Seattle, WA) as per vendor’s protocols. A
volume of 50 µl in duplicated of standards, blanks, controls, and samples were diluted
with 50 µl of 8M Guanidine-HCL and incubated for 15 minutes at room temperature. 50
µl of 0.3% (GuHCl) and incubated for 15 min at RT. A diluent composed of 0.3%
H2SO4 and 0.75% Triton X-100 was added to each vial and mixed at room temperature
for 15 minutes on a mechanical mixer. Once mixed, 750 µl of Alcian blue working
solution was added to each vial. To allow the Alcian blue to bind to the sGAG the vials
were incubated overnight at 4°C. The following day the vials were centrifuged at 12000
for 15 minutes. The supernatant was then removed and the pellet was resuspended in 500
µl DMSO solution and mixed for 15 minutes at room temperature. Following the
mixing, the vials were then centrifuged again as previously with the supernatant being
discarded and 500 µl of Gu-Prop (4M GuHCl + 33% 1-propanol + 0.25% Triton X-100)
was added. Once the pellet was dissolved the samples were loaded onto a 96-well plate
and the absorbance values were read at 620 nm on an EpochTM microplate
spectrophotometer (Bio-Tek, Winooski, VT), and the measured sGAG amounts were
normalized to the corresponding cell counts (n = 6 devices/condition for the healthy
monoculture and cocultures). This assay is based on the specific interactions between
sulfated GAGs and the tetravalent cationic dye Alcian blue, at low pH and optimized
ionic strength and has a working range of 12.5-400 µg/mL. Most data points were not
within this range increasing the amount of error. To obtain results a smaller standard
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curve was calculated using the low standards which allowed for the calculation of GAG
molecules in the lower ranges. It should be noted that this assay will not quantify the nonsulfated GAGs such as hyaluronic acid.

2.3.5. HA assay for hyaluronic acid synthesis
Hyaluronic acid synthesized and released by SMCs within the cellular matrix as well
as in the pooled spent medium was quantified using a hyaluronan enzyme-linked
immunosorbent quantitative assay (Echelon Biosciences Inc., Salt Lake City, UT). HA
concentration in the sample is determined using a standard curve of known HA amounts.
This assay works best with HA molecules that are greater than 25 repeating units.
Because this assay has a working limit depending on the number of repeating units it is
difficult in the scope of this study to ensure the presence of any HA molecules that are
shorter than 25 repeating units. A volume of 100 µl samples and standards were pipetted
in the provided 96-well incubation plate. To act as the zero HA control in this assay 100
µl of 1x HA diluent was utilized while for the blank control 150 µl of the diluent was
used. 50 µl of the diluted HA working detector was added to each of the wells except for
the ones filled with the blank controls. Following the addition of the diluted HA working
detector the plate was gently mixed and incubated for one hour at 37 °C. Once the
incubation period was complete 100 µl of the solution was transferred from each well to
the corresponding well in the pre-coated HA detection plate. The detection plate was
then incubated for 30 minutes at 4 °C and then each well was washed four times with 1x
wash concentrate making sure to invert and remove all wash concentrate onto an
absorbent paper towel. After the washing step was complete 100 µl of working enzyme
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was added to each well and incubated for 30 minutes at 37 °c. The washing procedure
described above was repeated following the incubation and 100 µl of working substrate
solution was added to each well. The detection plate was then incubated in the absence
of light at room temperature for 15 minutes and the absorbance was measured.
Absorbance values were read at 450 nm on an EpochTM spectrophotometer every 15
minutes until the ratio between the zero HA control and the 1600 ng/ml HA standard is
higher than 3. This ratio indicates the completion of the reaction and to add the stop
solution to each well. The measured HA content was normalized to the corresponding
cell counts (n = 6 devices/condition).

2.3.6. LOX functional activity
Studies have shown that lysyl oxidase (LOX) and LOX-like proteins are endogenous
enzymes responsible for crosslinking elastin precursor (tropoelastin) molecules. Thus,
estimating the endogenous LOX activity in the cellular matrix as well as in pooled
medium indicates the extent of cell-mediated crosslinking of tropoelastin to form mature
elastin matrix structures. Using a fluorometric assay (AmplexRed® Assay; Molecular
Probes, Eugene, OR), we assayed for LOX activity within the cell matrix and pooled
spent culture medium aliquots from different culture conditions. This assay works on the
principle that H2O2 will be released when LOX oxidatively deaminates alkyl
monoamines and diamines and has been used to detect as little as 10 pM of H2O2 in a
100µL volume (all measured values are above this detection limit). Firstly, the standards
were prepared (0, 2, 4, 6, 8, and 10 µM) and 50 µl of each standard and samples were
pipetted into a 96-well microplate with 50 µ of working solution (100µM Amplex Red
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reagent, 1:2, 0.2 U/ml Horseradish peroxidase). The microplate was then incubated in
the dark for 30 minutes at room temperature. Fluorescence intensities were recorded with
excitation and emission wavelengths of 560 and 590 nm, respectively (560 nm gave the
best standard curve and thus was used). The measured activity was normalized to the cell
density within that respective culture condition (n = 3 devices/condition).

2.3.7. Quantification of MMPs-2, 9 and TIMP-1 release
The amounts of MMPs-2 and 9 deposited within the cellular matrix as well as in the
pooled spent medium were quantified using MMP-2 ELISA (Boster Biological
Technology Co., Fremont, CA) and MMP-9 ELISA (R&D Systems, Inc., Minneapolis,
MN) assays as per vendor’s recommendations. The amount of TIMP-1 deposited within
the cellular matrix as well as in the pooled medium was quantified using a TIMP-1
ELISA (Boster Biological Technology Co.). The measured MMPs and TIMP-1 content
was normalized to the respective cell count within those cultures (n = 6
devices/condition). For the MMP-2 ELISA the sensitivity is < 10 pg/mL, MMP-9 ELISA
is <13 pg/mL, and TIMP-1 ELISA is < 3 pg/mL. Samples studied from the cell matrix
showed insignificant amounts of MMPs and TIMPs making it hard to accurately quantify
the actual amount of each protein however samples obtained from the pooled media all
showed values larger than the working limit.

2.3.7.1 Quantification of MMPs-2 and TIMP-1
The same provided protocol procedure was followed for both the MMPs-2 and TIMP1 assays. Firstly, each sample was diluted 2:1 with the provided diluent buffer and then
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100 µl of each sample was pipetted in the corresponding MMP-2 and TIMP-1 specific
antibody pre-coated 96-well plate. Following, 100 µl of the respective standards were
then pipetted into the respective plates. The microplates were then covered and incubated
at 37 °C for 90 minutes. Ensuing the incubation, each plate was carefully blotted on an
absorbent paper allowing the wells to dry and then the plates were incubated for one hour
at 37 °C with 100 µl biotinylated anti-rat MMP-2 and TIMP-1 antibody working
solutions added to their respective wells. Next, the solution was discarded from each
microplate and each well was then washed three times with 1x PBS. Following the
washing step, the plates were incubated with 100µl of 1x Avidin-Biotin-Peroxidase
Complex for 30 minutes at room temperature. The solution was then discarded and the
wells were washed five times with 1x PBS. 90 µl TBM color developing agent was then
added to each well and the plates were incubated at 37 °C for 30 minutes before the
reaction was terminated with 100 µl of TMB stop solution in each well. The absorbance
was read at 450 nm.

2.3.7.2 Quantification of MMPs-9
The MMP-9 ELISA assay is based on the quantitative enzyme-linked immunoassay
method where the MMP-9 binds to a specific monoclonal antibody and a specific
enzyme-linked polyclonal antibody. 50 µl of diluent RD1-34 was pipetted to each well in
the provided pre –coated 96-well plate with 50 µl of standards and samples. Once these
two were added the plate was then covered and incubated for two hours at room
temperature. Following the incubation, the wells were washed with wash buffer five
times and 100 µl of MMP-9 conjugate was added to each well. The incubation and
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washing step were repeated and then 100µl of substrate solution was added to each well.
Following the addition of the substrate solution the plate was incubated in dark at room
temperature for 30 minutes. Lastly, 100 µl of stop solution was added to each well and
the absorbance was measured at 450 nm and 570 nm. To obtain the standard curve and
thus the MMP-9 content the absorbance read at 570 nm was subtracted from 450 nm.

2.4. Immunofluorescence imaging of matrix proteins
The presence of elastin, fibrillin and LOX proteins within cell matrix were
qualitatively confirmed using immunofluorescence labeling (n = 3 devices/condition for
each protein). The presence of fibrillin within cell layers will confirm whether elastin
matrix formation was mediated by pre-deposition of a fibrillin scaffold. At 21 days, the
cell layers within microfluidic devices were fixed with 4% w/v paraformaldehyde for 15
min, and incubated with blocking serum (5% goat serum, 0.3% Triton-100 in phosphatebuffered saline; 20 min; 25 °C). Elastin, fibrillin and LOX were detected with respective
polyclonal antibodies (1% antibody in 1X PBS, 5% goat serum, 0.1% Trition-X, Elastin
Products; Abcam; Santa Cruz Biotechnology), which were incubated overnight at 4 °C on
a mechanical shaker. Once incubation was complete each cell culture was washed 3
times with 1x PBS, allowing 5 minute intervals between washes and then appropriate
secondary antibodies (0.4% antibody in 1x PBS, 5% goat serum, 0.1% Triton-X,
Chemicon, Temecula, CA) were added and incubated at room temperature in the dark for
20 minutes.

Cell nuclei were visualized with the nuclear stain 4’, 6- diamino-2-

phenylindole dihydrochloride (DAPI) contained in the mounting medium (Vectashield;
Vector Labs, Burlingame, CA) and 1X PBS was added to preserve cell culture till
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florescence imaging was performed. Images were acquired with a Zeiss Axiovert A1
florescence microscope equipped with Hamamatsu camera and image acquisition
software. Please see Table 2.1 for proper antibodies to be used in Immunofluorescence
imaging.
Table 2.1 Summary of antibodies used in immunofluorescence analysis.
Primary Antibody

Host

Clonality

Concentration (v/v)

Elastin

Rabbit

Polyclonal

1;100

LOX

Rabbit

Polyclonal

1;100

Fibrillin

Rabbit

Polyclonal

1;100

Secondary
Antibody
Goat anti-Rabbit

Host

Clonality

Concentration (v/v)

Goat

Poluclonal

1;250

2.5. Cellular Dimensions
The dimensions of the healthy and diseased phenotype were imaged using a Zeiss
Axiovert A1 florescence microscope equipped with Hamamatsu camera and image
acquisition software. Six cases per cell type were used and processed through ImageJ
software where each perimeter and area was calculated. Each case was sampled during
the 3-5 passages and seeded on a T-25 plate with Medium 231.

2.6. Statistical analysis
All biochemical data were obtained from three independent repeat experiments per
case, and were analyzed using Student’s t-test and one-way ANOVA, assuming unequal
variance and differences deemed significant for p < 0.05. The data were assumed to
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follow a near-Gaussian distribution in all the cases, and the mean and standard errors
were calculated accordingly.
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CHAPTER III

RESULTS AND DISCUSSION: HEALTHY HUMAN SMCS WITHIN
COCULTURES

3.1. HA-EC and HA-SMC proliferation
The proliferation of HA-ECs and HA-SMCs cultured in the presence or absence of
GSNO are shown in Fig. 3.1. In the absence of GSNO (controls), ECs proliferated ~ 3fold over 21 days, compared to their original seeding density (Fig. 3.1 A). The addition
of 1 or 10 nM GSNO promoted EC proliferation by ~4.1-fold and 4.8-fold respectively,
compared to day 1 seeding (p < 0.01 vs. controls in both the cases). Addition of 100 nM
GSNO offered no further benefit to EC proliferation compared to controls (p = 0.2 vs.
controls). In the presence or absence of GSNO, trends in SMC proliferation rates were
different from that of ECs. When SMCs were cultured alone in the absence of ECs,
increasing GSNO concentration suppressed SMC proliferation within 3D collagen
scaffolds over the 21 day period (Fig. 3.1 B). SMCs proliferated ~ 3.2-fold in the absence
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of GSNO, and that reduced to 2.9-fold, 2.4-fold and 2-fold respectively, in the presence
of 1, 10 and 100 nM GSNO (p < 0.01 for 0 nM vs. 10 nM or 100 nM; p < 0.01 for 1 nM
vs. 100 nM). In the presence of EC cocultures, SMCs proliferated almost 4.8-fold and
3.9-fold respectively, at 0 nM and 1 nM GSNO concentrations (p < 0.01 for EC coculture
vs. no coculture, under respective conditions; p < 0.01 for 0 nM vs. 1 nM GSNO).
However, SMC proliferation rates significantly decreased to 2-fold and 1.4-fold, with the
addition of 10 nM and 100 nM GSNO respectively, within cocultures (p < 0.01 for 10
nM vs. lower concentrations of GSNO; p < 0.01 for 100 nM vs. lower concentrations of
GSNO; p < 0.01 for 10 nM vs. 100 nM GSNO).
Previous studies have shown that the half-life of GSNO ranges from 5.5 h to 24 h,
depending on pH and environmental conditions82,91, and is considerably higher than that
of pure NO (typically a few minutes)92. Therefore, we choose to replace the culture
medium twice a day, so that fresh NO is delivered to the cells within cultures. Besides,
the NO release from GSNO concentrations tested here are within the physiological
levels92, which makes this study a good starting point for further in vivo optimization
studies. Given that NO is an unstable gas and endogenous NO levels are impossible to
quantify or manipulate, exogenous aerosolized NO delivery has been used to positively
modulate circulating levels of NO within cystic fibrosis patients93. In this study, we did
not investigate the NO activity and release rates from GSNO within culture media at
neutral pH, as it has been extensively reported earlier94,95. Given the low molecular
weight, it takes less than 20 min for GSNO (or NO) to diffuse across the 3D collagen
scaffold within the microfluidic device and saturate the entire cell culture region.
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Exogenously delivered NO has been shown to suppress proliferation of endothelial
cells derived from fetal bovine aorta and human umbilical veins in a dose-dependent
manner96, via an intracellular cGMP mechanism. In contrast, we noticed here that lower
GSNO dosage (1-10 nM) promoted modest HA-EC proliferation, while the stimulatory
effect was attenuated at 100 nM GSNO. Our results on the dose-dependent inhibitory
effects of GSNO on HA-SMC proliferation are in excellent agreement with similar
studies evaluating the role of NO donors (e.g., DEA NONOate, sodium nitroprusside,
nitroglycerin, SNAP) on human, rabbit, chick or rodent SMCs, both in vitro and in
vivo74,92,94,97. It is worth mentioning that cell toxicity was not noted within our cultures
(from LIVE/DEAD assay analysis; data not shown) in the presence of GSNO, and the
cell morphology appeared identical in both controls and test cases. SMC proliferation
data within cocultures was also in agreement with studies by Fillinger et al., who reported
that within bovine aortic cell 2D cocultures, ECs stimulated SMC proliferation by ~56%
compared to culturing SMCs alone98. Taken together, our results unequivocally suggest
that vascular cell proliferation is differentially modulated by exogenous NO delivery,
with significant implications in vascular remodeling under healthy and diseased
conditions.

Figure 3.1 (A) Fold increase in HA-EC density within 3D cultures supplemented with
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GSNO (0-100 nM). (B) Proliferation ratios of HA-SMCs in the presence or absence of
EC cocultures and GSNO (0-100 nM). Data shown represent mean ± standard error of
cell count after 21 days of culture, normalized to initial seeding density (n = 3/
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for
no cocultures vs. EC coculture, at a given GSNO dosage.

3.2. Total protein synthesis by HA-SMCs
The total protein amounts synthesized by HA-SMCs, in the presence or absence of
ECs, were quantified as two separate components: released into pooled spent media and
that deposited in cell matrix. HA-SMCs produced and deposited ~131 ± 19 ng of protein
within cell matrices, on a per cell basis, when cultured alone in the absence of GSNO
(Fig. 3.2 A). Although 1 and 100 nM GSNO offered no further benefits to protein
deposition within these SMC cultures, 10 nM GSNO significantly suppressed protein
deposition within SMC cultures (~ 67.8 ± 9 ng of protein; p < 0.001 for 10 nM vs. all the
other cases). On the other hand, coculturing SMCs with ECs did not improve protein
deposition in cell matrix in the absence of GSNO. Within EC cocultures, only 100 nM
GSNO stimulated a 2.2-fold increase in total protein deposition within cell layers,
compared to GSNO-free cultures (p < 0.001 for 100 nM vs. lower GSNO doses).
HA-SMCs released ~ 2 ± 0.15 µg of protein into pooled media on a per cell basis,
over the 21 day culture, in the absence of EC cultures and GSNO (Fig. 3.2 B). While the
addition of 1 nM and 10 nM GSNO did not alter these amounts, 100 nM GSNO
upregulated protein release by 1.54-fold compared to non-additive controls (p = 0.008).
Surprisingly, coculturing with ECs significantly suppressed protein release into pooled
media by SMCs, on a per cell basis, compared to their stand-alone cultures (Fig. 3.2 B; p
< 0.001 for no coculture vs. EC coculture controls). Addition of 1 nM GSNO did not
rescue this decrease in protein synthesis and release by SMCs within cocultures.
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However, 10 nM and 100 nM GSNO addition stimulated 1.42- and 3.66- fold increases in
protein synthesis by SMCs within EC cocultures, compared to controls (p = 0.026 and p
< 0.001, respectively, compared to controls). Taken together, results suggest that 100 nM
GSNO dosage significantly increased total protein synthesis, release into pooled media
and deposition within cell matrix layers, in the presence or absence of EC cocultures.
The effects of NO on matrix protein synthesis by SMCs or any other mammalian cell
types has been reported in a very few studies thus far. Kolpakov et al. have shown that
NO donors such as SNAP (0.4-1.2 mM) and SNP (0.1-0.5 mM) inhibited total protein
synthesis and collagen synthesis by rabbit aortic SMCs in vitro in a reversible but dosedependent manner99, highlighting the strong role of NO in modulating SMC phenotype.
In another study, SNAP inhibited total protein synthesis by rat aortic SMCs in a timedependent manner, when cultured in the presence of 5% fetal calf serum100. Curran et al.
have shown that SNAP inhibited total protein synthesis by hepatocytes in a reversible but
dose-dependent manner101. These results are in agreement with our observations, where
NO delivered via GSNO did not significantly enhance total protein synthesis by HASMCs, except at 100 nM dosage and EC coculture. Although the molecular mechanisms
behind this NO-mediated inhibition of protein synthesis by SMCs remains categorically
unexplored and beyond the scope of this work, previous studies suggest that multiple
biochemical pathways might be involved in mediating this process99.
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Figure 3.2 Total protein amounts deposited within cell matrix (A) or released into pooled
media (B), when GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the
presence or absence of HA-EC cocultures. Data shown represent mean ± standard error
of protein synthesis after 21 days of culture, normalized to cell count within respective
cases (n = 6/ condition). * indicates p < 0.05 compared to GSNO-free cultures; #
indicates p < 0.01 for no cocultures vs. EC coculture, at a given GSNO dosage.

3.3. Elastin synthesis and deposition by HA-SMCs
The total elastin synthesized by HA-SMCs was quantified as that released into pooled
media (i.e., tropoelastin) and that deposited into the cell layers (i.e., matrix elastin). In the
absence of EC coculture and GSNO, HA-SMCs released 7.05 ± 1.1 ng of tropoelastin on
a per cell basis over the 21 day culture (Fig. 3.3 A). Within SMC cultures, the
tropoelastin content increased to 11.8 ± 2.2, 42.3 ± 5.4 and 29.9 ± 4.7 ng respectively, in
the addition of 1, 10 and 100 nM GSNO (p < 0.01 for 0 nM vs. higher GSNO dosages).
Thus, in the absence of EC cocultures, 10 nM GSNO appeared to stimulate higher
tropoelastin synthesis and release by HA-SMCs (p < 0.01 vs. all other GSNO dosages).
Even in the absence of GSNO, coculturing with ECs stimulated significantly higher
amounts of tropoelastin release by SMCs (Fig. 3.3 A; 20.6 ± 3.8 ng per cell) compared to
that within no coculture cases (p < 0.001 for EC coculture vs. no coculture). Within
cocultures, addition of 10 nM or 100 nM GSNO furthered tropoelastin synthesis by 2.4-
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and 3.2- fold respectively, compared to that seen in controls (p < 0.001 for 0 nM vs. 10
nM or 100 nM GSNO). However, no significant benefit of cocultures to tropoelastin
synthesis was noted at 1 nM GSNO dosage.
In the absence of EC cocultures, matrix elastin deposited within HA-SMC cultures
was undetectable at 0 nM GSNO (Fig. 3.3 B). However, with increasing GSNO dosage,
matrix elastin amounts on a per cell basis increased in a linear fashion, with significant
differences noted between incremental GSNO dosages (p < 0.01 for 0 nM vs. 1 nM, 1 nM
vs. 10 nM, and 10 nM vs. 100 nM). Even in the absence of GSNO, coculturing with ECs
resulted in the deposition of 1.76 ± 0.25 ng of matrix elastin by SMCs, on a per cell basis.
Within EC cocultures, addition of 1, 10 and 100 nM GSNO resulted in 1.2-, 2.9- and 4fold increases in matrix elastin synthesis on a per cell basis, compared to GSNO-free
controls (p < 0.01 for 10 nM vs. 0 nM, and for 100 nM vs. 0 nM). Taken together, results
suggest that (a) although adult HA-SMCs produce quantifiable tropoelastin over the 21
day culture period, they do not deposit detectable amounts of matrix elastin, in the
absence of GSNO; (b) coculturing with ECs significantly upregulated tropoelastin and
matrix elastin by adult HA-SMCs, even in the absence of GSNO; (c) GSNO addition
significantly enhanced both tropoelastin release and matrix elastin deposition by SMCs in
a dose-dependent manner, in the presence or absence of EC cocultures; and (d) EC
coculture and 100 nM GSNO synergistically contributed to multi-fold increases in tropoand matrix elastin by adult HA-SMCs.
From the data shown in Figs. 3.3 A and B, the matrix elastin yield (ratio of matrix
elastin to the total elastin produced) within these HA-SMC cultures was calculated. When
SMCs were cultured alone in the absence of ECs, the matrix elastin yields were 5%, 2.3%
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and 4.1% within 1 nM, 10 nM and 100 nM GSNO additive-cultures, respectively.
However, EC cocultures significantly enhanced matrix elastin yields, both in the presence
or absence of GSNO. The matrix elastin yield within 0 nM, 10 nM and 100 nM GSNO
additive cultures were 7.8%, 9.3% and 9.8%, respectively (p < 0.001 for no coculture vs.
EC coculture, at respective GSNO doses). Surprisingly, addition of 1 nM GSNO resulted
in ~ 40% matrix elastin yield, significantly higher than that noticed in all the other
coculture cases.
Despite recent progress in the field of vascular tissue engineering, elastin synthesis
and deposition by vascular SMCs within 3D constructs remain a formidable
challenge102,103. This is partially due to highly reduced ability of adult SMCs (at both
transcription and translation levels) to synthesize, release, and deposit mature elastin.
Thus, the overarching goal of cellular or tissue engineering approaches is to stimulate
these adult SMCs, using an optimal combination of biochemical and biomechanical cues,
to deposit mature and cross-linked elastin within blood vessels. In a series of studies, we
have shown that exogenous cues such as hyaluronan oligomers, TGF-ß1, IGF-1 and LOX
induced increases in elastin synthesis within 2D cultures of adult rat aortic SMCs89,104–107.
In a series of recent studies, Lin et al. have shown that surface topography strongly
affects elastin gene expression and protein synthesis by adult human coronary artery
SMCs108,109. Elastin gene expression and protein synthesis by these cells increased
significantly when cultured within 3D porous polyurethane scaffolds compared to their
2D culture counterparts, and the addition of TGF-ß1 to these cultures furthered these
trends. Such increases in elastin expression by SMCs within these 3D scaffolds were
facilitated by Ras-ERK1/2 signal transduction pathways. However, these cells were
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cultured only up to 14 days, which is not sufficient for elastin matrix deposition and
maturation within cell layers. Ramamurthi and coworkers recently showed that adult
human and rat SMCs produced higher elastin protein within 3D collagen gels exposed to
exogenous growth factors or cyclical stretching conditions110,111. These studies point to
the overall superiority of 3D scaffolds over 2D cultures, in stimulating elastin synthesis
and release by SMCs.
Thus, in this study, we cultured HA-SMCs within 3D collagen scaffolds to mimic
physiological conditions, and enable future tissue engineering based approaches for in
situ elastin regeneration. We noted multi-fold increases in tropoelastin production and
matrix elastin deposition within HA-SMC 3D cultures, in the presence of GSNO and EC
cocultures. A study by Sugitani et al. was the only known report which evaluated the role
of NO on elastin expression and synthesis by chick aortic SMCs74. Although elastin
deposition into matrix was not evaluated by them, results showed NO to stimulate
tropoelastin mRNA expression, synthesis and release into pooled media by chick cells in
a dose-dependent manner (1-100 nM), with the maximum stimulation noted at 100 nM
GSNO. In our current study, the excellent elastin matrix yield of ~40% noticed within 1
nM GSNO and EC cocultures was not only relevant to vascular biology studies, but also
highly encouraging from tissue engineering and regenerative medicine based standpoints. However, further studies are needed to quantify the changes in elastin gene
expressions under these culture conditions.
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3.4. Glycosaminoglycan synthesis by HA-SMCs
Studies have shown that chondroitin sulfate and heparan sulfate were the main
constituents of sGAGs produced by human aortic SMCs112. Suarez et al. have shown that
growth factors such as EGF, FGF and VEGF stimulate SMCs to synthesize heparin
sulfate in a dose-dependent manner113. However, the role of NO or EC cocultures in
mediating GAG (sulfated or non-sulfated) synthesis remains unexplored, and this study
reports for the first time the dose-dependent effects of NO donors on GAG synthesis by
human aortic SMCs. In general, the GAG content within the cell layers and pooled media
was quantified as sulfated GAGs (sGAGs) and non-sulfated GAGs (HA). In the absence
of EC cocultures, adult HA-SMCs released 16.7 ± 3.2 ng of sGAGs into pooled media on
a per cell basis, within GSNO-free cultures (Fig. 3.3 C). GSNO addition (1-100 nM)
significantly suppressed sGAG release into pooled media when compared to controls (p <
0.001). On the other hand, no further benefit of EC coculture to sGAG release into pooled
media was noticed within GSNO-free cultures. Within EC cocultures, addition of 1 nM
GSNO suppressed sGAG release by SMCs (p < 0.01 for 1 nM vs. 0 nM), while 10 and
100 nM GSNO stimulated 1.4–fold and 1.95–fold increases in sGAG release
respectively, compared to controls (p < 0.01 for 0 nM vs. 10 nM or 100 nM; p < 0.01 for
1 nM vs. 10 nM or 100 nM; p < 0.01 for 10 nM vs. 100 nM GSNO). Taken together,
except within GSNO-free cultures where significant differences were not noticed,
coculturing with HA-ECs appeared to stimulate sGAG release by HA-SMCs in a GSNO
dose-dependent manner.
The sGAG content deposited within cell matrices seem to reflect the trends observed
in matrix elastin synthesis by HA-SMCs. sGAGs presence could not be detected within
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HA-SMC cell layers in the absence of EC coculture and GSNO (Fig. 3.3 D). However, in
the absence of EC cocultures, increasing GSNO concentration from 1-100 nM promoted
significant sGAGs deposition in the cell layers in a dose-dependent manner (p < 0.01 for
1 nM vs. 10 nM or 100 nM; p < 0.01 for 10 nM vs. 100 nM). In the presence of EC
cocultures, SMCs deposited 0.62 ± 0.19 ng of sGAGs in the cell layers, on a per cell
basis, within GSNO-free cultures. While 1 and 10 nM GSNO did not further promote
sGAG deposition into matrix layers within EC cocultures, addition of 100 nM promoted a
drastic 7.4-fold increase in sGAG deposition within cell layers, relative to GSNO-free
controls (p < 0.001 for 100 nM vs. lower GSNO doses). In general, the matrix sGAG
yield (ratio of matrix sGAG content to the total sGAGs produced) within SMC cultures
ranged between 0 - 10 %, while EC cocultures significantly promoted the same to
between 4.2 - 14.5 %. Taken together, results show that 100 nM GSNO stimulated
synthesis, release and deposition of sGAGs by HA-SMCs within a biomimetic vascular
coculture environment.
The release of non-sulfated GAGs within SMC cultures was different from sGAG
trends. SMCs released ~ 2 ± 0.23 pg of HA into pooled media on a per cell basis, in the
absence of GSNO and EC cocultures (Fig. 3.3 E). Although no further benefits to HA
release were realized at lower GSNO dosages (1 and 10 nM), a 1.55-fold increase in HA
content was noted at 100 nM GSNO relative to controls (p < 0.01 for 100 nM vs. lower
doses of GSNO). However, in the presence of EC cocultures, GSNO at 0 nM and 1 nM
suppressed HA release by SMCs into pooled media, although this suppression was
rescued at higher GSNO dosages. HA release into pooled media was enhanced by 2.4fold and 3.2-fold, within cultures supplemented with 10 and 100 nM GSNO respectively,
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within EC cocultures (p < 0.001 for both cases vs. 0 nM cultures). The trends in HA
deposition within cell matrix (Fig. 3.3 F) mirrors that noted in sGAG deposition within
respective cultures. When SMCs were cultured alone, 0.2 ± 0.03 pg of HA was deposited
within cell layers on a per cell basis, and addition of GSNO at 1 and 10 nM dosages did
not further enhance these deposition levels. However, in the presence of 100 nM GSNO,
a 2.44-fold increase in HA deposition was seen (p < 0.001 for 100 nM vs. lower GSNO
dosages), even in the absence of EC cocultures. Interestingly, no additional benefits of
EC coculture to HA matrix deposition was noted at 0 nM or 1 nM GSNO dosages (Fig.
3.3 F). A dramatic 2.56-fold and 21.9-fold increase in HA deposition within cell layers
was noted when GSNO was supplemented at 10 nM and 100 nM respectively, to SMCs
within EC cocultures.
Quantification of HA matrix yield (ratio of HA within cell matrix to total HA
synthesis) revealed that the yield increased from ~ 9% within 0-10 nM GSNO cultures to
13.4% within 100 nM GSNO-additive cultures, in the absence of EC cocultures.
However, when SMCs were cocultured with ECs, the yields increased from ~ 14% within
0-10 nM GSNO cases to a dramatic 51% within 100 nM GSNO additive cultures. Taken
together, results show that 100 nM GSNO might help in the synthesis, release and
deposition of hyaluronic acid by human aortic SMCs within biomimetic vascular
coculture environment. Our future studies are designed to elucidate the molecular weight
ranges of hyaluronic acid fragments synthesized and released under respective
conditions.
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Figure 3.3 When GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the
presence or absence of EC cocultures, elastin protein released into pooled media (A) or
deposited within cell matrix (B), sulfated GAGs released into pooled media (C) or
deposited within cell matrix (D), and HA released into pooled media (E) or deposited
within cell matrix (F) was quantified. Data shown represent mean ± standard error of
protein synthesis after 21 days of culture, normalized to cell count within respective cases
(n = 6/ condition). * indicates p < 0.05 compared to GSNO-free cultures; # indicates p <
0.01 for no cocultures vs. EC coculture, at a given GSNO dosage.
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3.5. LOX enzyme activity
LOX has been shown to play an important role in the crosslinking and maintenance of
ECM proteins such as elastin and collagen, and thus expected to participate in ECM
remodeling associated with cardiovascular diseases. However, LOX synthesis and
activity within adult HA-SMC cultures has not been identified earlier. In this study, the
LOX enzymatic activity was quantified within the cell matrix and pooled media to (a)
establish the stand-alone and synergistic benefits of GSNO and EC cocultures to LOX
activity, and (b) determine whether a correlation exists between LOX enzymatic activity
and matrix protein yields within respective cultures. In the absence of EC cocultures and
GSNO, LOX activity within pooled media from HA-SMC cultures was quite low (0.076
± 0.002 nM on a per cell basis; Fig. 3.4 A). These basal levels were drastically increased
by 10.6-, 12.3- and 20.9–fold, with the addition of 1, 10 and 100 nM GSNO, respectively
(p < 0.001 for 0 nM vs. higher GSNO dosages; p < 0.001 for 1 nM vs. 100 nM; p < 0.001
for 10 nM vs. 100 nM). In GSNO-free cultures, coculturing with ECs resulted in a 4.2fold increase in LOX activity within pooled media, compared to that within SMC cultures
(p < 0.001). These levels were furthered by 3.9-, 6.2- and 34.8-fold, respectively, with the
addition of 1, 10 and 100 nM GSNO to SMC-EC cocultures (p < 0.001 vs. controls in all
the cases).
The basal levels (at 0 nM GSNO) of LOX activity within cell matrix of SMC cultures
(0.067 ± 0.014 nM) increased by 1.65-fold, 2.97-fold and 5.5-fold, respectively, with the
addition of 1, 10 and 100 nM GSNO (Fig. 3.4 B; p < 0.01 for 0 nM vs. higher GSNO
doses; p < 0.01 for 1 nM vs. higher GSNO doses; p < 0.01 for 10 nM vs. 100 nM). EC
coculture provided no significant benefit to LOX activity within cell matrix, in the
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absence of GSNO. Surprisingly, 1 and 10 nM GSNO inhibited LOX activity within cell
matrices in the presence of EC cocultures, while 100 nM GSNO promoted a dramatic
10.6-fold increase (p < 0.001 for 100 nM vs. lower dosages). This dramatic increase in
LOX activity within cell matrix at 100 nM GSNO dosage, in the presence or absence of
EC cocultures, partially explains the multi-fold increases in HA, elastin and sGAG
deposition within HA-SMC cell matrices. The only other known report on the effects of
NO on LOX synthesis showed a 4.5-fold increase in LOX mRNA expression within
chick aortic SMC cultures, with the addition of 100 nM GSNO74. We hypothesize that the
dramatic increases in LOX activity seen at 100 nM GSNO and EC cocultures in our study
might be due to significant increase in LOX mRNA expression, which would be
investigated in our future studies.

Figure 3.4 LOX enzyme activity within pooled media (A) or within cell matrix (B),
when GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the presence or
absence of HA-EC cocultures. Data shown represent mean ± standard error of LOX
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6
per condition). * indicates p < 0.05 compared to GSNO-free cultures; # indicates p < 0.01
for no cocultures vs. EC coculture, at a given GSNO dosage.
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3.6. Release of MMPs-2, 9 and TIMP
In this study, the amounts of MMPs-2, 9 and TIMP into pooled media was quantified
on a per cell basis (Fig. 3.5). The amounts of these enzymes were insignificant to be
accurately quantifiable in cell matrix. In the absence of EC coculture and GSNO, HASMCs released ~ 25 pg of MMP-2 on a per cell basis (Fig. 3.5 A). The addition of 1-100
nM GSNO to SMC cultures suppressed MMP-2 release by 50-70% on a per cell basis (p
< 0.01 for 0 nM vs. higher GSNO dosages; p < 0.01 for 1 nM vs. higher GSNO dosages).
Coculturing with ECs suppressed MMP-2 release by SMCs, in the absence of GSNO.
The average MMP-2 release within EC cocultures increased from 11.6 pg within controls
(0 nM GSNO) to ~ 15 pg within 1 nM GSNO and to ~ 26 pg within 10 and 100 nM
GSNO cultures (p < 0.01 for 0 nM vs. 10 or 100 nM GSNO, within cocultures). On the
other hand, MMP-9 levels increased marginally within SMC cultures in the presence of
GSNO, compared to GSNO-free cultures (Fig. 3.5 B; p < 0.01 for 0 nM vs. higher GSNO
dosage; p < 0.01 for 1 nM vs. 100 nM; p < 0.01 for 10 nM vs. 100 nM). Within EC
cocultures, MMP-9 levels were inhibited at lower GSNO concentrations (0-10 nM)
compared to SMC cultures, although 100 nM GSNO increased MMP-9 release by SMCs
for reasons not clear at this stage.
In the absence of cocultures and GSNO, HA-SMCs produced 1.57 ± 0.39 pg of
TIMP-1 on a per cell basis (Fig. 3.5 C). These TIMP-1 levels were significantly
suppressed by addition of 1 nM GSNO (p < 0.01 for 1 nM vs. 0 nM GSNO), while 10
and 100 nM GSNO offered only marginal benefits compared to controls. Within EC
cocultures, although 1 nM GSNO did not enhance basal levels of TIMP-1 release by HASMCs (3.05 ± 0.6 pg per cell; p = 0.22 for 1 nM vs. 0 nM), 10 and 100 nM GSNO
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promoted 1.96-fold and 2.1-fold increases in TIMP-1 release into pooled media (p <
0.001 vs. 0 nM GSNO in both cases; p < 0.001 vs. 1 nM GSNO in both the cases). In
general, higher levels of TIMP-1 release were noted in cocultures compared to when
SMCs cultured alone. Taken together, these results suggest that (a) exogenous GSNO
supplementation suppressed MMP-2 and marginally enhanced MMP-9 release when HASMCs were cultured alone, (b) MMPs levels increased within cocultures with increasing
GSNO, and (c) higher GSNO dosages enhanced the release of TIMP-1 by HA-SMCs in
the presence of HA-EC cocultures.
Matrix metalloproteinases, specifically MMP-2 and MMP-9, play an important role in
degrading basement membrane and ECM microenvironment, thus facilitating SMC
migration during injury or disease (atherosclerosis, aneurysms, angioplasty, etc.)
conditions in vasculature. On the other hand, naturally-available tissue inhibitors of
MMPs (e.g., TIMP-1) released by SMCs contribute to reduction in such ECM
breakdown, SMC migration and inflammation levels. Thus, a balance (or lack thereof) of
these two components contributes to changes in SMC phenotype from quiescent to
migratory and invasive nature. However, the specific levels of MMPs and TIMPs
synthesized by adult human vascular SMCs within 3D biomimetic cultures are not
known. Besides, very few studies explored the role of nitric oxide in regulating MMPs
and TIMP levels within vasculature, under healthy or diseased conditions. In a recent
study, Dey et al. reported on the molecular pathways involved in NO-mediated release of
MMPs and TIMP by rat aortic SMCs in vitro114. They noted that in the presence of
DETA NONOate, an NO donor, rat SMCs synthesized and secreted more MMP-2 and
less amounts of MMP-9, while TIMP-2 levels increased as well. We hypothesize that the
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higher levels of MMPs and TIMP-1 noted within cocultures might be due to the
combined release from SMCs and ECs, although further experiments are needed to
quantify their release from ECs alone, and the effects of paracrine signaling between HAECs and HA-SMCs.

Figure 3.5 When GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the
presence or absence of EC cocultures, the release of MMP-2 (A), MMP-9 (B), and
TIMP-1 (C) into pooled media was quantified. Data shown represent mean ± standard
error of protein synthesis after 21 days of culture, normalized to cell count within
respective cases (n = 3 per condition). * indicates p < 0.05 compared to GSNO-free
cultures; # indicates p < 0.01 for no cocultures vs. EC coculture, at a given GSNO
dosage.

3.7. Immunofluorescence labeling of Elastin, Fibrillin and LOX
Immunofluorescence images under these culture conditions qualitatively support the
elastin and LOX deposition within cell matrix layers discussed above. When SMCs were
cultured alone within 3D scaffolds (Fig. 3.6), significantly higher staining for matrix
elastin was noted within cultures supplemented with 10 and 100 nM GSNO, compared to
that at 0 and 1 nM GSNO. Similar increases in LOX deposition was noted within cultures
receiving higher dosages of GSNO. Although coculturing with HA-ECs resulted in
higher amounts of matrix elastin deposition at all GSNO dosages, the staining intensity
was more pronounced at higher GSNO concentrations (10 and 100 nM; Fig. 3.7). In
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strong agreement with quantitative data, a robust staining for LOX within 100 nM GSNO
additive cultures was apparent, when SMCs were cocultured with ECs. Images from
negative control cultures (stained without primary antibody) showed no coloration (data
not shown). In general, staining for these proteins was evident in different planes of focus
within these 3D gels. These data are in broad agreement with the quantitative data on
matrix elastin (Fig. 3.3 B) and LOX activity (Fig. 3.4 B) within respective cultures.
While staining for fibrillin expression could be seen within all the cases, it was modest
and seems to be confined to the periphery of the cells. It also raises the possibility that
adult human aortic SMCs do not produce much fibrillin, although further studies are
needed to precisely measure the ability of HA-SMCs to synthesize and deposit protein
fibers (fibrillin, fibulins, MAGPs, etc.) important for elastin assembly and maturation.
Our current studies are geared towards elucidating the ultrastructure of the matrix
proteins (e.g., fibrillar, co-localization), using characterization tools such as transmission
electron microscopy.
It could be seen that the combined amount of elastin and GAGs (quantified in Figs.
3.3 and 3.4), in both pooled media and cell matrix, and is much lower than that quantified
from BCA assay (Fig. 3.2). This suggests that in addition to elastin and GAGs, numerous
other proteins such as collagens and proteoglycans, might be released and deposited by
HA-SMCs within 3D scaffolds, which we intend to quantify in our future studies.
Intuitively, we speculate that changing the composition or stiffness of the 3D scaffold (2
mg/ml type-1 collagen) used in this study, might influence the cell proliferation and
matrix synthesis outcomes by HA-SMCs in the presence of GSNO. Besides, results from
this study pose a few challenging questions: Does exogenous GSNO addition stimulate
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endogenous NO release by HA-ECs, and if so, is there a dose-dependency affect? At 100
nM GSNO addition, what cytokines and chemokines are being released by SMCs and/or
ECs, and are they influencing the multi-fold increases noted in protein release and matrix
deposition? Our current studies are geared towards investigating these phenomena within
our culture system. Nevertheless, a systematic understanding of the complex pathways
involved in NO-mediated SMC signaling is essential in formulating pharmaceutical
approaches for the treatment of vascular degenerative diseases.

Figure 3.6 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited
by HA-SMCs within cell matrix layers, in the presence of GSNO (0-100 nM). HA-SMCs
were cultured alone within 3D scaffolds, in the absence of cocultures with endothelial
cells.

52

Figure 3.7 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited
by HA-SMCs within cell matrix layers, in the presence of GSNO (0-100 nM). HA-SMCs
were cultured within 3D scaffolds, in the presence of cocultures with human aortic
endothelial cells.
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CHAPTER IV

RESULTS AND DISCUSSION: ANEURYSMAL HUMAN SMCS IN 2D AND 3D
CULTURES

4.1. Aneurysmal HA-SMC proliferation
For 2D and 3D cultures, we seeded at roughly 10,000 cells in each well, as measured
by hemocytometer analysis. However, we performed a quantitative cell density analysis
on day 1 after seeding to accurately measure the number of cells seeded and for both
cases ~7,800 cells were seeded in each case. The proliferation of diseased HA-SMCs
cultured in 2D and 3D, both in the presence and absence of GSNO is shown in Fig. 4.1.
In the absence of GSNO the SMCs proliferated 2.8-fold in 2D, and roughly doubled in
3D gels (p < 0.05 vs. 2D control) at 21 days cultured. The addition of 100 nM GSNO
decreased the SMC proliferation in both 2D and 3D to 2.05-fold (p < 0.05 vs. 2D control)
and 1.3-fold (p < 0.05 vs. 2D control, p < 0.05 vs. 3D control) respectively.
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Figure 4.1 (A) Fold increase in human aneurysmal SMC density within 3D cultures
supplemented with GSNO (0-100 nM). Data shown represent mean ± standard error of
cell count after 21 days of culture, normalized to initial seeding density (n = 3/
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for
2D vs. 3D, at a given GSNO dosage.

It is also important to note that the GSNO dose used in this study was identified from
our previous study (Chapter III) where a range of GSNO doses were tested to upregulate
the ECM components. Just like our past study, we did not investigate the NO activity
and release rates from GSNO within culture media at neutral pH, as this data has been
previously reported94,95. Previous studies utilizing the aneurysmal SMCs show ~4.2 fold
increase in cell proliferation under normal conditions in 2D115. Alternately, in a study
involving rat aneurysm SMCs proliferated 2.5± 0.32 fold over 21 days116. The data
obtained in this study was found to be between the results obtained in previous
experiments in 2D and the absence of GSNO. There is still no work that looks at the
addition of GSNO in 3D cultures of aneurysmal SMCs and the data obtained in this
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experiment shows a slight decrease in the proliferation of SMCs when compared to the
data shown in Chapter III.

4.2. Total protein synthesis by aneurysmal HA-SMCs
The total protein amount synthesized by the diseased HA-SMCs, cultured in both 2D
and 3D, under the presence or absence of GSNO is quantified in Fig. 4.2. The total
protein amounts were quantified as two separate components: released into the pooled
spent media and the protein deposited in the cell matrix. Diseased HA-SMCs synthesized
and deposited 16.2 ± 2.4 ng and 266.4 ± 40 ng (p < 0.05 vs. 2D control) of protein, on a
per cell basis, in 2D and 3D cultures respectively. With the addition of GSNO there was
a significant multi-fold increase in the total protein in the cell matrix in both the 2D and
3D cultures, compared to cultures that lacked GSNO (p < 0.05 vs. 2D control and p <
0.05 vs. 3D control). Also, there was a significant difference between the total protein on
a per cell basis that was deposited in the cell matrix between the 2D and 3D cultures in
the presence of GSNO (p < 0.05 vs. GSNO-free controls in both 2D and 3D). The total
protein synthesized on a per cell basis and released into the pooled spent media in the
absence of GSNO was 16.8 ± 2.5 µg and 37.9 ± 5.7 µg (p < 0.05 for 3D vs. 2D) 2D and
3D cultures, respectively. Similar to that seen in the cell matrix, there was a significant
increase in the total protein synthesized and released into the pooled spent media with the
addition of GSNO: 34.6 ± 5.2 µg in 2D cultures and 52.7 ± 7.9 µg within 3D cultures,
respectively (p < 0.05 vs. 2D control, p < 0.05 vs. 3D control and p < 0.05 vs. 2D with
GSNO).
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A

B
V

Figure 4.2 Total protein amounts deposited within cell matrix (A) or released into pooled
media (B), when GSNO (0, 100 nM) was supplemented to human aneurysmal SMC
cultures, in 2D and 3D cultures. Data shown represent mean ± standard error of protein
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6/
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for
2D vs. 3D, at a given GSNO dosage.

4.3. Elastin synthesis and deposition by aneurysmal HA-SMCs
The total elastin synthesized by diseased HA-SMCs was quantified as that released
into the pooled spent media (i.e., tropoelastin) or that deposited into the cell layers (i.e.,
matrix elastin). The elastin deposited into the cell matrix was 0.56 ± 0.08 pg in 2D
cultures, and 0.81 ± 0.12 pg within 3D cultures (p < 0.05 for 2D vs. 3D). Upon addition
of GSNO, two opposite trends were noticed. The 2D cultures induced less matrix elastin
in the cell layers than in the absence of GSNO (p < 0.05 vs. 2D control), while the 3D
cultures promoted deposition of significantly higher matrix elastin amounts in the
presence of GSNO (p < 0.05 vs. 3D control; p < 0.05 for 3D vs. 2D with GSNO). The
elastin deposited in the cell layers (i.e., matrix yield) is significantly lower compared to
the elastin released into the pooled media. Within GSNO-free controls, elastin released
into the pooled media (tropoelastin) was 152.8 ± 22.9 pg in 2D and 169.23 ± 25.4 pg in
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3D, which are not significantly different. When GSNO was added, the 2D cultures did
not have a significant change in the tropoelastin released, while there was a larger
increase in the release of tropoelastin within 3D cultures (p < 0.05 vs. 3D control; p <
0.05 for 3D vs. 2D with GSNO).
From the data shown in Figs. 4.3 A and B, the matrix elastin yield (ratio of matrix
elastin to the total elastin produced) within aneurysm HA-SMC cultures was calculated.
When aneurysm SMCs were cultured in 2D, the matrix elastin yields were 0.4% and
0.08% within 0 nM and 100 nM GSNO additive-cultures, respectively. However, 3D
cultures modest enhanced matrix elastin yields, both in the presence or absence of
GSNO. The matrix elastin yield within 0 nM and 100 nM GSNO additive cultures were
0.5% and 0.8%, respectively.
In this study we cultured human aneurysmal SMCs in both 3D collagen scaffolds and
on collagen-coated 2D plastic plates. The 3D cultures allow us to mimic physiological
conditions and enable future tissue engineering based approaches for in situ elastin
regeneration. We noted an increase in tropoelastin production as well as matrix elastin
deposition within 3D cultures under the presence of GSNO cocultures. These results
confirm our hypothesis that delivering exogenous NO cues to aneurysmal SMCs might
help promote protein synthesis, release and deposition within 3D cultures, in addition to
regulating their proliferation behavior. Rat aneurysmal SMCs under the presence of
different exogenously supplemented cues showed a 1 to 1.6 fold increase in the total
amount of elastin compared to 2D culture controls116. Similar results were observed in
our 2D and 3D cultures with the 3D culture being similar to the largest increase observed
in previous studies.
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A

B

Figure 4.3 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC
cultures, in 2D or 3D cultures, elastin protein released into pooled media (A) or deposited
within cell matrix (B). Data shown represent mean ± standard error of protein synthesis
after 21 days of culture, normalized to cell count within respective cases (n = 6/
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for
2D vs. 3D, at a given GSNO dosage.

4.4. Glycosaminoglycan synthesis by aneurysmal HA-SMCs
Our past study (Chapter III) reported for the first time the dose-dependent effects of
NO donors on the GAG synthesis by human aortic SMCs117.

The total sGAG

synthesized by the diseased HA-SMCs, cultured in both 2D and 3D, under the presence
or absence of GSNO is quantified in Fig. 4.4. The sGAGs deposited into the cell matrix
in the absence of GSNO is 0.14 ± 0.02 pg within 2D cultures, and 0.86 ± 0.13 pg within
3D cultures (p < 0.05 vs. 2D control). The addition of GSNO increased the deposition of
sGAGs on a per cell basis in both the 2D and 3D cultures: 0.38 ± 0.06 pg (p < 0.05 vs.
2D control) and 1.3 ± 0.2 pg (p < 0.05 vs. 3D control; p < 0.05 vs. 2D with GSNO),
respectively. Similar trends were seen in the sGAGs released into the pooled media,
although the amounts were two orders of magnitude higher. The sGAGs released into the
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pooled media in the absence of GSNO is 15.8 ± 2.4 pg in 2D cultures, and 36.4 ± 5.5 pg
within 3D cultures (p < 0.05 vs. 2D control). The addition of GSNO increased the
release of sGAGs on a per cell basis in both the 2D and 3D cultures: 34.4 ± 5.2 pg (p <
0.05 vs. 2D control) and 62.9 ± 9.4 pg (p < 0.05 vs. 3D control and p < 0.05 vs. 2D with
GSNO) respectively.
From the data shown in Figs. 4.4 A and B, the matrix GAG yield (ratio of matrix
GAG to the total GAG produced) within aneurysm HA-SMC cultures was calculated.
When aneurysm SMCs were cultured in 2D, the matrix GAG yields were 0.9% and 2.3%
within 0 nM and 100 nM GSNO additive-cultures, respectively. 3D cultures did not show
any significant enhancement of matrix GAG yields, both in the presence or absence of
GSNO. The matrix GAG yield within 0 nM and 100 nM GSNO additive cultures were
1.1% and 2%, respectively.
The release of non-sulfated GAGs (i.e., HA) synthesized by the diseased HA-SMCs,
cultured in both 2D and 3D, under the presence or absence of GSNO is quantified in Fig.
4.5. HA deposited into the cell matrix in the absence of GSNO is 0.36 ± 0.05 pg in 2D
cultures and 0.57 ± 0.08 pg in 3D cultures (p < 0.05 vs. 2D control). The addition of
GSNO modestly increased the deposition of HAs on a per cell basis in both the 2D and
3D cultures: 0.51 ± 0.08 pg (p < 0.05 vs. 2D control) and 0.77 ± 0.11 pg (p < 0.05 vs. 3D
control and p < 0.05 vs. 2D with GSNO) respectively. Similar trends were seen in the
HA released into the pooled media. HA released into the pooled media in the absence of
GSNO is 22.86 ± 3.4 pg within 2D cultures, and 27.66 ± 4.1 pg within 3D cultures,
which are not significantly different. The addition of GSNO increased the release of HA
on a per cell basis in both 2D and 3D cultures: 29.75 ± 4.5 pg (p < 0.05 vs. 2D control)
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and 40.71 ± 6.1 pg (p < 0.05 vs. 3D control and p < 0.05 vs. 2D with GSNO)
respectively.
From the data shown in Figs. 4.5 A and B, the matrix HA yield (ratio of matrix HA to
the total HA produced) within aneurysm HA-SMC cultures was calculated. When
aneurysm SMCs were cultured in 2D, the matrix HA yields were 1.6% and 1.7% within 0
nM and 100 nM GSNO additive-cultures, respectively. However, 3D cultures modest
enhanced matrix HA yields, both in the presence or absence of GSNO. The matrix HA
yield within 0 nM and 100 nM GSNO additive cultures were 2% and 1.9%, respectively.

A

B

Figure 4.4 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC
cultures, in 2D or 3D cultures, sulfated GAGs released into pooled media (A) or
deposited within cell matrix (B). Data shown represent mean ± standard error of protein
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6/
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for
2D vs. 3D, at a given GSNO dosage.
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B

Figure 4.5 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC
cultures, in 2D or 3D cultures, HA released into pooled media (A) or deposited within
cell matrix (B). Data shown represent mean ± standard error of protein synthesis after 21
days of culture, normalized to cell count within respective cases (n = 6/ condition). *
indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 2D vs. 3D, at
a given GSNO dosage.

4.5. LOX- protein synthesis and activity
The activity of LOX-proteins synthesized by aneurysmal HA-SMCs in both 2D and
3D cultures can be seen in Fig. 4.6. The LOX proteins deposited in the cell layers in the
absence of GSNO were 0.025 ± 0.004 pM within 2D cultures and 0.11 ± 0.016 pM in 3D
cultures (p < 0.001 for 3D vs. 2D). While the addition of GSNO to 2D cultures did not
induce a significant change in LOX activity within cell matrix, it induced ~2.5-fold
increase in LOX activity within 3D cultures (p < 0.05 vs. 3D control; p < 0.0001 vs. 2D
with GSNO).

When considering the LOX activity within pooled media under no

exogenous GSNO addition, there was a large difference in the amounts quantified in 2D
vs. 3D cultures: 0.185 ± 0.03 pM and 2.76 ± 0.4 pM (p < 0.05 vs. 2D control)
respectively. Surprisingly, the addition of GSNO to 3D cultures did not significantly
62

alter LOX activity, compared to GSNO absence. However, within 2D cultures, LOX
activity increased multifold with the addition of GSNO (p < 0.001 vs. 2D control). It is
important to note that the LOX released into the pooled media in the 3D cultures was still
significantly larger than the 2D cultures (p < 0.05 vs. 2D with GSNO). Rat aneurysmal
SMCs under the presence of different exogenously supplemented cues showed a 1 to 1.7
fold increase in the total amount of LOX proteins compared to 2D culture controls116.
Similar results were observed in our 3D cultures. However, with ~12 fold increase the
2D culture in this experiment shows a large upregulation of the LOX protein when under
the influence of GSNO compared to other exogenously supplemented cues in the rat
model.

A

B

Figure 4.6 LOX enzyme activity within pooled media (A) or within cell matrix (B),
when GSNO (0, 100 nM) was supplemented to human aneurysmal SMC cultures, in 2D
and 3D cultures. Data shown represent mean ± standard error of LOX synthesis after 21
days of culture, normalized to cell count within respective cases (n = 6 per condition). *
indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 2D vs. 3D, at
a given GSNO dosage.
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4.6. MMPs-2, 9 and TIMP-1 protein synthesis
The production of all MMPs and TIMPs for their release into the pooled spent media
in 2D and 3D can be seen in Fig. 4.7. The deposition of these proteins in the cell matrix
was too low to be reported. As for the MMP-2 release into the pooled media, the control
levels quantified were not significantly different from each other in 2D (5.99 ± 0.9 pg) vs.
3D (7.61 ± 1.1 pg) cultures. With the addition of GSNO, although the 2D cultures did
not induce any significant change, there was a significant increase in MMP-2 release
within 3D cultures (p < 0.05 vs. 3D control; p < 0.05 vs. 2D with GSNO). Similar trends
were noted for MMP-9 release as well. Although no significantly different values were
noted within GSNO-free 2D and 3D cultures, the addition of GSNO induced a
significantly higher increase in the release of MMP-9 within 3D cultures compared to the
3D control (p < 0.05vs. 3D control). TIMP-1 release into the pooled media was
quantified at 0.53 ± 0.08 pg in 2D and 0.68 ± 0.1 pg in 3D cultures, in the absence of
GSNO. The addition of GSNO induced a significant increase in both the 2D and 3D
cultures. Within 2D cultures, it increased to 0.71 ± 0.1 pg (p < 0.05 vs. 2D control),
while within 3D cultures it increased to 1.82 ± 0.27 pg (p < 0.05 vs. 3D control and p <
0.05 vs. 2D with GSNO). Rat aneurysmal SMCs under the presence of different
exogenously supplemented cues showed a 1.1 to 1.6 and 0.9 to 2 fold increase in the total
amount of MMP-2 and MMP-9, respectively, compared to 2D culture controls116.
Studies have shown that NO upregulated MMP enzymes in melanoma cell lines as well
as in pulmonary tissue, and although the exact cause is still unknown it is believed that
NO molecule or one of the partially reduced forms was responsible for that result118,119.
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The addition of GSNO showed to follow the same trends as the hyaluronan oligomers
and TGF-ß1 for both 2D and 3D cultures.

A

B

C

Figure 4.7 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC
cultures, in 2D and 3D cultures, the release of MMP-2 (A), MMP-9 (B), and TIMP-1 (C)
into pooled media was quantified. Data shown represent mean ± standard error of protein
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 3
per condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01
for 2D vs. 3D, at a given GSNO dosage.

4.7. Immunofluorescence labeling of Elastin, Fibrillin and LOX
Immunofluorescence images under these culture conditions qualitatively support the
elastin and LOX deposition within cell matrix layers discussed above. When aneurysmal
SMCs were cultured alone within 3D scaffolds, significantly higher staining for matrix
elastin was noted within cultures supplemented with 100 nM GSNO, compared to that at
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0 nM GSNO and both 2D scaffold conditions (Fig. 4.8). Similar increases in LOX
deposition was noted within 3D cultures receiving the dose of GSNO.

In strong

agreement with quantitative data, a robust staining for LOX within 100 nM GSNO
additive cultures was apparent, for both the 2D and 3D cultures. Images from negative
control cultures (stained without primary antibody) showed no coloration (data not
shown). In general, staining for these proteins was evident in different planes of focus
within these 3D gels. These data are in broad agreement with the quantitative data on
matrix elastin (Fig. 4.3) and LOX activity (Fig. 4.6) within respective cultures. While
staining for fibrillin and LOX expression could be seen within all the cases, it was modest
and seems to be confined to the periphery of the cells. It also raises the possibility that
diseased adult human aortic SMCs do not produce much fibrillin or LOX, although
further studies are needed to precisely measure the ability of HA-SMCs to synthesize and
deposit protein fibers (fibrillin, fibulins, MAGPs, etc.) important for elastin assembly and
maturation.
It could be seen that the combined amount of elastin and GAGs (quantified in Figs.
4.3 and 4.4), in both pooled media and cell matrix, and is much lower than that quantified
from BCA assay (Fig. 4.2). This suggests that in addition to elastin and GAGs, numerous
other proteins such as collagens and proteoglycans, might be released and deposited by
HA-SMCs within 2D and 3D scaffolds, which we intend to quantify in our future studies.
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Figure 4.8 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited
by HA-SMCs within cell matrix layers, in the presence of GSNO (0, 100 nM). HA-SMCs
were cultured alone within 2D and 3D scaffolds.

4.8. Dimension measurements of both aneurysmal and healthy SMC
The dimensions of healthy and diseased SMCs within 2D cultures lacking any GSNO
are shown in. This data shows that in diseased conditions, the overall area and perimeter
significantly increased when compared to the healthy condition. It is important to note
that these cells came from different donors which can lead to a difference in size among
the cells.
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Table 4.1 Summary of cell dimension measurements.
Healthy

Area (µm2)

1
2
3
4
5
6

5395.892
3341.64
4019.314
8869.18
3349.1
7125.839

Perim.
(µm)
517.88
376.03
431.657
668.517
512.516
689.759

Average

5350.160833

532.7265
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Diseased

Area (µm2)

1
2
3
4
5
6

6817.193
32128
4449.49
6602.274
3270.119
3679.142

Perim.
(µm)
864.848
1866.53
574.567
580.818
442.134
667.762

Average

9491.03633

832.7765

A

B

Figure 4.9 Comparison of healthy (A) and aneurysmal (B) SMCs at 5× in T-25 flask
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CHAPTER V

CONCLUSIONS AND RECOMMENDATIONS

5.1. Healthy SMCs within cocultures
This study is based on the hypothesis that robust synthesis, organization and
maturation of elastin and GAGs within adult blood vessels could be accomplished, on
demand, by exogenously delivering NO cues which proffer developmental signals and
stimulate the intrinsic elastogenesis capability of adult human aortic SMCs. Accordingly,
a novel biomimetic, 3D cellular engineering approach has been developed and tested to
evaluate the stand-alone and synergistic effects of NO and EC cocultures on the synthesis
and deposition of matrix proteins on demand, which has not been attempted earlier. The
following are the key conclusions from this study:
 We have shown that in the cases of both HA-SMCs cultured alone and in
cocultures with HA-ECs, there is a suppression of the HA-SMC proliferation as
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the dose of GSNO increased. This trend is not followed by the HA-EC cultures
under the influence of GSNO.
 GSNO also encouraged multi-fold increases in the total ECM protein synthesis
deposited into the cell matrix as well as released into the pooled media, with the
most upregulation occurring at the 100 nM dose of GSNO.
 In general, addition of GSNO promoted increases in the ECM protein (elastin,
GAGs, HA, and LOX) release as well as deposition into the cell matrix.
 The benefits of GSNO further increased in the presence of HA-EC cocultures.
 The matrix metalloproteinases that regulate the ECM protein of the vascular
tissue and their inhibitors have also been affected by both the exogenously
delivered GSNO and the HA-EC coculture. For the most part these enzymes as
well as their inhibitors increased in the presence of GSNO and even more so
under coculture conditions except for MMP-2 in the absence of coculture.
 Immunofluorescence labeling of both elastin and LOX qualitatively supports the
deposition within cell matrices as quantified from biochemical assays.

The

staining for fibrillin could be seen modestly in all the cases, and it was
predominately confined to the periphery of the cells.
5.2. Aneurysmal SMC in 2D and 3D cultures
 The proliferation of diseased aneurysmal HA-SMCs was suppressed in the
presence of 100 nM GSNO in both 2D and 3D cultures.
 The total protein synthesized by the diseased cells (deposited and released into the
pooled media) in both 2D and 3D cultures increased with the addition of 100 nM
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GSNO. Also there was a significant upregulation of protein synthesis in the 3D
cultures compared to the 2D cultures.
 The general trend of the specific ECM proteins studied (elastin, GAGs, HAs, and
LOX) show a general upregulation in the presence of 100 nM GSNO. The trends
showed on average a significant larger protein synthesis in 3D cultures than the
2D cultures.
 With the addition of 100 nM GSNO, the release of MMP-2, 9, and TIMP-1
showed a significant increase in the 2D cultures. As for the 3D cultures, there
was only a significant increase in the presence of GSNO for the MMP-2 and
TIMP-1. Finally, in the presence of GSNO, the values of MMP-2, 9, and TIMP-1
in 3D cultures were significantly larger than their 2D counterparts.
 Immunofluorescence labeling of both elastin and LOX qualitatively supports the
deposition within cell matrices as previously discussed. The staining for fibrillin
could be seen modestly in all cases it was predominately confined to the periphery
of the cells.
 Overall the addition of GSNO significantly upregulates the ECM proteins
necessary for homeostasis of diseased smooth muscle tissue.

The overall

proliferation and protein creation is minimal when compared to that of healthy
tissue, so either higher concentrations of GSNO are needed, or more treatment
time is necessary to return normal function to diseased HA-SMCs.
 The overall dimensions of the diseased cells in 2D were larger than the healthy
SMCs, which can possibly explain the low amount of ECM release and deposition
in the diseased assays when compared to the healthy experiments.

72

 ECM data obtained in aneurysm cell lines is much lower than the values obtained
in healthy SMCs even though they follow similar trends.
5.3. Recommendations
The following are recommendations for future studies to further understand the
effects of both nitric oxide as well as other possible factors in synthesis and regulation of
vascular smooth muscle tissue.
 Test the role of fluid flow on cell behavior through a pulsatile pump attached to
the described microfluidic device.
 Investigate the role of ECM microenvironment on cell migration, proliferation
and matrix remodeling.
 Study the matrix synthesis and deposition by diseased adult human aortic smooth
muscle cells within 3D biomimetic cocultures under the influence of nitric oxide.
 Relevant drug and toxicology screening, tissue engineering and regenerative
medicine therapies, as well as vascular disease remodeling in vivo.
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